Stocktoria
Ernexa Therapeutics Inc. ERNA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1991-08-29
Ernexa Therapeutics Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | $582,000 | $68,000 | $0 | — |
| Gross profit | — | $486,000 | -$168,000 | $0 | — |
| Operating income | -$9.3M | -$15.7M | -$21.1M | -$33.2M | -$113.7M |
| Interest expense | — | — | $614,000 | $30,000 | — |
| Income tax | -$45,000 | $30,000 | -$3,000 | $45,000 | $64,000 |
| Net income | -$14.1M | -$44.5M | -$21.7M | -$24.6M | -$122.5M |
| EPS (diluted) | $-2.24 | $-48.96 | $-4.08 | $-8.06 | $-56.61 |
| Operating cash flow | -$7.0M | -$15.8M | -$20.4M | -$21.0M | -$23.5M |
| Free cash flow | -$7.1M | -$16.2M | -$20.4M | -$21.3M | -$23.6M |
| Cash & equivalents | — | $1.7M | $7.6M | $11.4M | $17.0M |
| Total assets | $5.8M | $5.3M | $49.1M | $22.3M | $31.5M |
| Total liabilities | $3.4M | $3.6M | $46.9M | $10.2M | $6.0M |
| Shareholders' equity | $2.4M | $1.7M | $2.2M | $12.1M | $25.5M |
Source: SEC EDGAR filings · CIK 0000748592 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.